Piper Sandler Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $210
Needham Maintains Masimo(MASI.US) With Hold Rating
Cautious Optimism Amid Leadership Change and Strategic Uncertainty at Masimo
Masimo Brings 'Satisfying' Conclusion to CEO Search -- Market Talk
BTIG Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $178
BTIG Remains a Buy on Masimo (MASI)
Masimo Taps Katie Szyman as Permanent CEO
Masimo: Changes Are Effective as of Feb 12 >MASI
Express News | Masimo Corp - Michelle Brennan Named Chairman of Masimo's Board
Express News | Masimo Corp -Katie Szyman Appointed Chief Executive Officer and to Board of Directors
Masimo Announces Leadership Transition
Stifel Maintains Masimo(MASI.US) With Buy Rating
GEHC Stock Gains on Long-Term Collaboration With Sutter Health
A Quick Look at Today's Ratings for Masimo(MASI.US), With a Forecast Between $178 to $193
Masimo's Strong Performance and Promising Outlook: Buy Rating Affirmed
Needham Reiterates Hold on Masimoto Hold
Needham Sticks to Their Hold Rating for Masimo (MASI)
Masimo Announces Preliminary Q4 2024 Revenue At $601M, Up 9%; Healthcare Revenue At $368M, Up 8%; FY24 Revenue At $2.094B, Up 2%; Healthcare Revenue At $1.395B, Up 9%; Non-GAAP EPS Exceeds $4.10; FY25 Guidance Includes Healthcare Revenue Growth Up To...
Express News | Masimo Corp - Full-Year 2024 Non-Gaap EPS Expected to Be More Than $4.10
Masimo Sees 2024 More Than Adj EPS $4.10 >MASI